Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Potency equivalence of botulinum toxin preparations.
Formulation composition of botulinum toxins in clinical use.
The use of botulinum toxin (BoNT) has now become the treatment of choice for a range of debilitating neuromuscular diseases and for aesthetic medicine. BoNT products are licensed as prescription-only… Expand
Biochemical, functional and potency characteristics of type A botulinum toxin in clinical use
Dysport? (botulinum type A toxin; BoNT-A) 500 LD50 unit vial was first licensed for clinical use in 1990. Inter-batch reproducibility and comparability of the Dysport toxin?haemagglutinin complex… Expand
Comparison of type a botulinum toxin products in clinical use
To the Editor, Type A botulinum toxin products are being increasingly used in a range of debilitating clinical conditions, notably head and neck dystonias, cerebral palsy and post-stroke… Expand
The protein load of therapeutic botulinum toxins
Sirs, The dose standardization of the two main type A botulinum toxin products (Dysport , Slough, UK and Botox , Irvine, CA, USA) has often been discussed in the literature over the last 15 years.… Expand
Botulinum Toxin as a Clinical Product: Manufacture and Pharmacology
- A. Pickett
The use of botulinum neurotoxins as clinical products has required the development of suitable manufacturing processes meeting the highest standards of safety and quality for pharmaceutical products.… Expand
Dysport: pharmacological properties and factors that influence toxin action.
- A. Pickett
- Biology, Medicine
- Toxicon : official journal of the International…
- 1 October 2009
The pharmacological properties of Dysport that influence toxin action are reviewed and compared with other botulinum toxin products. In particular, the subject of diffusion is examined and discussed… Expand
Serious issues relating to the clinical use of unlicensed botulinum toxin products.
Reconstruction of spatially orientated myotubes in vitro using electrospun, parallel microfibre arrays.
- Alexander Huber, A. Pickett, K. Shakesheff
- Chemistry, Medicine
- European cells & materials
- 8 October 2007
The stable culture of myogenic cells and their differentiation into myotubes in vitro is often hindered by the mechanical destabilisation of the spontaneously contractile neotissue formed, resulting… Expand